TCF4 and CD4+/CD56+ hematodermic neoplasm: Although the expression of these markers raises the possibility of BPDCN, a definitive diagnosis relies on the demonstration of tumor cells expressing more specific pDC markers such as CD303, TCF4 and TCL1.